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Abstract
Introduction Patients with sepsis suffer high morbidity and
mortality. We sought to conduct a systematic review of the
literature to evaluate the association between hemodynamic
goals of therapy and patient outcomes.
Methods We conducted a comprehensive search of the
literature to systematically review hemodynamic goals used in
clinical trials in patients with sepsis. We searched the literature
using the Pubmed (1965–June 2006), Embase (1974–June
2006), CINAHL (1982–June 2006), pre-CINAHL, and
Cochrane Library (2006, issue 3) electronic databases on 1
August 2006 for the following terms: sepsis, septic shock,
severe sepsis, human clinical trials. We also hand-searched
references and our personal files. Studies were selected if they
met all of the following criteria: randomized, controlled trial study
design; enrollment of adult patients with sepsis; presence of a
hemodynamic goal for patient management; > 24-hour follow-
up; and survival included as an outcome. Studies were
independently selected and reviewed by two investigators.
Results A total of 6,006 citations were retrieved, and 13 eligible
articles were reviewed. Mean arterial pressure was a treatment
goal in nine studies, and systolic blood pressure was a treatment
goal in three studies. A goal for pulmonary artery occlusion
pressure, central venous pressure, and cardiac index was given
in four, three, and five studies, respectively. The range of
hemodynamic goals used in the trials were: mean arterial
pressure 60–100 mmHg, central venous pressure 6–13 mmHg,
pulmonary artery occlusion pressure 13–17 mmHg, and cardiac
index 3–6 l/min/m2. All trials that used a systolic blood pressure
goal used 90 mmHg as the aim.
Conclusion For those trials that specify hemodynamic goals,
the wide range of treatment targets suggest a lack of agreement
on blood pressure and filling pressure goals for management of
patients with sepsis. There was also inconsistency between
trials in which measures were targeted. Further research is
necessary to determine whether this lack of consistency in
hemodynamic goals may contribute to heterogeneity in
treatment effects for clinical trials of novel sepsis therapies.
Introduction
Standard therapy for patients with septic shock includes anti-
biotics, infection source control, and hemodynamic support
with fluids and vasoactive medications. Despite these thera-
pies, the mortality rate for patients with sepsis remains high at
17–50% [1-3]. Recent advances in understanding the patho-
physiology of sepsis have led to preclinical trials that
attempted to modulate the inflammatory and coagulation path-
ways. Despite promising pathophysiological rationales derived
from preclinical trials, most clinical trials of agents that were
successful in preclinical trials did not demonstrate improved
outcomes in patients with sepsis. It is unclear whether the fail-
ure to replicate the success of anti-sepsis agents seen in pre-
clinical trials was due to the agents tested, to the
hemodynamic goals of therapy chosen, or to the failure of pre-
clinical models to reflect clinical infections.
MAP = mean arterial pressure; TNF = tumor necrosis factor.Critical Care    Vol 11 No 3    Sevransky et al.
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The Surviving Sepsis Campaign published guidelines for the
hemodynamic support of patients with sepsis [4]. These rec-
ommendations for treatment, however, are based primarily on
expert opinion, small non-randomized trials, and short-term tri-
als primarily aimed at demonstrating physiological principles.
Hemodynamic goals vary widely among hospitals. Little is
known about the variation in hemodynamic goals in clinical tri-
als and whether this variation is associated with patient out-
comes. To better understand the hemodynamic goals in
clinical trials in the sepsis research, and to inform future
research into anti-sepsis agents, we performed a systematic
review of the literature.
Methods
Study selection criteria
Studies eligible for the present review met the following crite-
ria: randomized, controlled trial study design; enrollment of
adult patients with sepsis; presence of a hemodynamic goal
for patient management; > 24-hour follow-up; and survival
included as an outcome. The latter two requirements served to
eliminate studies that were exclusively designed to measure
organ function over a limited time period since this endpoint
may be an inadequate surrogate for mortality in trials of novel
sepsis therapies [5,6].
Search strategy
We conducted a comprehensive search of the literature using
Medline from 1 January 1965 to 1 June 2006, with the follow-
ing medical subject heading terms: sepsis OR severe sepsis
OR septic shock AND human clinical trials. Using similar
terms, we also searched the Embase (1974–June 2006),
CINAHL (1982–June 2006), pre-CINAHL, and Cochrane
Library (2006, issue 3) electronic databases on 1 August
2006. We hand-searched references of relevant review arti-
cles [4,5,7] and our personal files.
Study selection
Two investigators (JES, SN) independently reviewed citations
based on the selection criteria. The abstracts of all citations
selected by either of the investigators and the full-text articles
for all eligible abstracts were independently reviewed by two
investigators (JES, GMS). Agreement between reviewers was
calculated by both the percentage agreement and kappa sta-
tistics. Disagreement regarding eligibility was resolved by
consensus.
Data extraction, synthesis, and study quality
For each eligible full-text article, two authors (JES, GMS) inde-
pendently abstracted measures of patient baseline character-
istics, the duration of the trial, and mortality rates. To
summarize the hemodynamic goals of each trial, both meas-
ure(s) of the blood pressure and/or filling pressure used and/
or the cardiac index, and the target range for each measure,
were abstracted for each trial.
We evaluated study quality according to the following criteria:
(1) appropriate patient selection – identification of sepsis
using accepted diagnostic criteria [8], (2) control for co-inter-
ventions – standardized protocol for volume resuscitation prior
to initiating vasopressors, and (3) appropriate analysis using
the criteria proposed by Jadad and colleagues [9]. We used
these criteria to comment on the methodological quality of
studies, but did not exclude studies from the review based on
this evaluation. Since the trials tested the efficacy of different
sepsis agents and used different outcome measures, we
could not synthesize the effect of the therapies on patient out-
comes either quantitatively or qualitatively; instead, our objec-
tive was to understand the goals used for hemodynamic
management of patients across these clinical trials of sepsis.
Hemodynamic criteria
We examined the Methods sections for hemodynamic treat-
ment goals for the clinical sepsis trials. We abstracted both
treatment measures (for example, central venous pressure,
mean arterial pressure (MAP)) and the hemodynamic goals of
treatment (for example, central venous pressure of 8 mmHg).
Hemodynamic measures and goals that were listed as part of
the trial entry criteria but were not included as part of a man-
dated treatment strategy were excluded. We separately
abstracted criteria for treatment and control groups in trials
that tested specific hemodynamic endpoints. If a range of val-
ues were specified during the trial, we used the mean of the
range of values specified.
Results
We identified 6,006 citations from our search strategy, of
which 242 abstracts and 126 full-text articles were reviewed
(Figure 1). Of these full-text articles, 10 did not enroll sepsis
patients, five were secondary analysis that did not include pri-
mary data, and three were not randomized controlled trials. Of
the remaining 104 studies, 76 (73%) did not include hemody-
namic goals for patient management. Ultimately, 13 articles
met our eligibility criteria (Table 1). Reviewer agreement on
selection of eligible citations was 99% (κ = 0.79) and on
selection of full-text articles was 100% (κ = 1.0).
Table 3 summarizes the measures of study quality for the eligi-
ble trials. All studies reported sepsis criteria that were based
on the American College of Chest Physicians/Society of Crit-
ical Care Medicine consensus criteria for entry into the clinical
trial [8]. Only three studies (23%) reported a specific protocol
for volume resuscitation, while 10 studies (76%) reported
some measurement of organ function. Four studies (31%) met
one Jadad and colleagues' criteria for study quality, six studies
(46%) met two criteria, and three studies (23%) met three cri-
teria [9].
For blood pressure goals, nine studies (69%) included MAP
goals, with the minimum MAP and maximum target MAP rang-
ing from 60 to 100 mmHg (Table 2). Seven of these studiesAvailable online http://ccforum.com/content/11/3/R67
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(54%) used MAP goals that fell within the range of 60–70
mmHg (Figure 2a), with the remaining two studies using 80
and 100 mmHg [10,11]. Three studies (23%) used a systolic
blood pressure goal, with all studies targeting > 90 mmHg
[10-12]. One study did not include any blood pressure goal
[13].
For filling pressure goals, a central venous pressure goal was
used in three studies (23%) [14-16] (see Figure 2b), with tar-
get goals that ranged from 6 to 13.5 mmHg. A pulmonary
artery occlusion pressure goal was used in four studies (31%),
with the target ranging from 13 to 17 mmHg [10,12,17,18]
(see Figure 2c). A cardiac index goal was listed in five studies
(38%) [12,16,19-21], with the target ranging from 3 to 6 l/
min/m2 (Figure 2d). One study used separate hemodynamic
goals for the treatment and control arms [12]. Another study
specified oxygen delivery goals [18]. In all, eight studies (61%)
required a pulmonary artery catheter as part of the study pro-
cedures. Of note, one of these studies that required the use of
a pulmonary artery catheter as part of the protocol did not
specify treatment goals that would require the use of the cath-
eter [11].
Three studies in the present review were designed to test spe-
cific hemodynamic treatment paradigms. Rivers and col-
leagues demonstrated that early goal-directed therapy over a
six hour period resulted in a 12.6% absolute decrease in 60-
day mortality for patients with severe sepsis [14]. Alia and col-
leagues examined the role of goal-directed therapy in patients
with established severe sepsis and septic shock [18], and
Tuchschmidt and colleagues examined the role of goal-
directed therapy in septic shock [12]. The studies of both
Tuchschmidt and Alia and colleagues included a treatment
arm that specified supranormal therapeutic goals [12,18]. The
other 10 studies incorporated specific hemodynamic goals
into trials of novel therapies specifically directed at the
pathophysiology of sepsis. Analysis of the studies excluding
the two trials that include supranormal therapeutic goals does
not alter the variability in treatment goals seen in the present
review, with the exception of a narrowed cardiac index range
(data not shown).
Discussion
The present systematic review of hemodynamic goals in sep-
sis clinical trials has two major findings. First, of the 126 clini-
cal studies that were reviewed in full, 73% did not include
hemodynamic goals of therapy. Of the 13 studies that met our
inclusion criteria, there was a wide range of targeted hemody-
namic goals and measures. Importantly, not all studies
included similar targets or measures.
Most of the studies used MAP as their hemodynamic measure
for directing sepsis therapy. Only three of the studies used
systolic blood pressure as a measure, with all three selecting
90 mmHg as the target [10-12]. While the American College
of Chest Physicians/Society of Critical Care Medicine consen-
sus definition uses systolic blood pressure as a marker of
hypotension [8], some experts suggest that the MAP may be
more closely associated with organ perfusion [22]. The choice
of different measures in these studies may reflect variation in
practice between clinicians in blood pressure targets for
patients with sepsis.
Table 1
Study description
Reference n Year Number of centers Study population Follow-up duration for mortalitya
Tuchsmidt and colleagues [12] 51 1992 1 Septic shock 14 days
Peake and colleagues [10] 20 1996 1 Septic shock Hospital stay
Bollaert and colleagues [11] 40 1998 2 Septic shock 28 days
Spapen and colleagues [19] 22 1998 1 Septic shock Hospital stay
Alia and colleagues [18] 63 1998 1 Severe sepsis, septic shock Intensive care unit stay
Clark and colleagues [23] 56 1998 1 Severe sepsis 40 days
Boldt and colleagues [15] 28 1999 1 Sepsis, trauma 5 days
Briegel and colleagues [17] 40 1999 1 Septic shock 365 days
Rivers and colleagues [14] 263 2001 1 Sepsis, severe sepsis, septic shock 60 days
Cole and colleagues [13] 24 2002 1 Severe sepsis, septic shock Hospital stay
Emet and colleagues [16] 53 2004 1 Severe sepsis Hospital stay
Bakker and colleagues [20] 312 2004 48 Septic shock 28 days
Lopez and colleagues [21] 797 2004 128 Septic shock 28 days
aIf mortality was provided for more than one time point, the time point of the primary outcome measure was reported.Critical Care    Vol 11 No 3    Sevransky et al.
Page 4 of 9
(page number not for citation purposes)
Figure 1
Study flow diagram Study flow diagram. RCT, randomized controlled trial.Available online http://ccforum.com/content/11/3/R67
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In two of the studies, the MAP goal was higher than in the
other studies. First, in a trial of a nonspecific nitric oxide
synthase inhibitor the target MAP was between 70 and 90
mmHg, with an actual mean MAP of 86 mmHg achieved in
both the treatment and control groups [21]. This trial was the
first sepsis trial to demonstrate a statistically significant result,
with an increase in the mortality rate for the treatment (versus
placebo) group. Second, a trial of a chimeric monoclonal anti-
body to TNF-α targeted a MAP of between 90 and 110 mmHg
[23]. In this trial there was no difference in mortality rates
between the study groups. The differing results in the these
two trials may have been caused by differing sample sizes of
the trials, differing agents used, or other unmeasured co-inter-
ventions. Achieving a higher MAP may lower cardiac output,
oxygen delivery, and regional perfusion, thus modifying the
effects of sepsis therapies.
Only 54% of the studies provided a filling pressure goal as
part of the treatment regimen. Three studies mandated central
venous pressure goals while four studies mandated a pulmo-
nary artery occlusion pressure goal. Adequate volume resusci-
tation is an essential part of hemodynamic management. While
some recent studies have cast doubt on whether the pulmo-
nary artery occlusion pressure represents an adequate surro-
gate for left ventricular end-diastolic volume or whether use of
the pulmonary artery catheter can improve outcomes in
patients with sepsis [24,25], the wide range of treatment goals
and measures and the absence of a filling pressure goal in the
majority of studies suggests heterogeneity in thought as
regards filling pressure targets in patients with sepsis. Similar
heterogeneity is seen in the cardiac index goals in the studies
that included such goals.
Given the past and present interest in goal-directed therapy
for patients with sepsis, we had hypothesized that a greater
number of studies would be eligible for this review. Rivers and
colleagues demonstrated that early goal-directed therapy over
a 6-hour period for patients with severe sepsis that started in
the emergency room improved outcomes [14]. It is notable
that this study, in contrast to previous studies, used central
venous oxygen saturation as compared with the cardiac out-
put and mixed venous oxygen saturation measurements. Many
of these studies that did not meet our inclusion criteria, how-
ever, enrolled patients who did not have sepsis but only were
at risk for sepsis [26]. Furthermore, only a few studies of spe-
cific agents aimed at modulating the inflammatory cascade
Table 2
Study treatments, outcomes, and hemodynamic measurements
Reference Treatment n Control group 
mortality
Study group mortality Blood pressure goal Other hemodynamic goals
Tuchsmidt and colleagues 
[12]
Elevation of cardiac 
output with 
dobutamine and 
fluids
51 18/25 (72%) 13/26 (50%) SBP > 90 mmHg Treatment group: PAOP ≥ 15 
mmHg and CI ≥ 6 l/min/m2; 
control group: CI ≥ 3 l/min/m2
Peake and colleagues [10] N-acetyl-cysteine 20 5/10 (50%) 9/10 (90%) SBP > 90 mmHg CI ≥ 4 l/min/m2; PAOP 15–18 
mmHg
Bollaert and colleagues [11] Supraphysiologic 
hydrocortisone
40 12/19 (63%) 7/21 (32%) SBP > 90 mmHg
Spapen and colleagues [19] N-acetyl-cysteine 22 4/10 (40%) 5/12 (41.6%) MAP > 65 mmHg CI > 4 l/min/m2
Alia and colleagues [18] Maximizing of oxygen 
delivery with 
dobutamine
63 21/32 (65.6%) 23/31 (74.5%) MAP > 60 mmHg PAOP 12–15 mmHg; 
treatment group: DO2I > 600 
ml/min/m2; control group: 
DO2I > 330 ml/min/m2
Boldt and colleagues [15] Heparin 56 11/28 (39.2%) 10/28 (35.7%) MAP > 65 mmHg CVP 12–15 mmHg
Clark and colleagues [23] TNF-α antibody 28 3/14 (21.4%) 3/14 (21.4%) MAP 90–110 mmHg
Briegel and colleagues [17] Stress dose 
hydrocortisone
40 6/20 (30%) 5/20 (25%) MAP > 70 mmHg PAOP 12–15 mmHg
Rivers and colleagues [14] Multifaceted early 
goal-directed therapy 
protocol
263 70/133 (52.6) 50/130 (38.4) MAP ≥ 65 mmHg CVP 8–12 mmHg, EGDT 
SVO2 ≥ 70%
Cole and colleagues [13] Continuous 
hemofiltration
24 4/12 (33.3%) 4/12 (33.3%) MAP ≥ 70 mmHg
Emet and colleagues [16] N-acetyl-cysteine 53 8/26 (30.7%) 7/27 (25.9%) CVP 4–8 mmHg
Bakker and colleagues [20] Nitric oxide synthase 
inhibitor
312 75/155 (48.3%) 72/155 (46.2%) MAP ≥ 70 mmHg CI ≥ 3 l/min/m2
Lopez and colleagues [21] Nitric oxide synthase 
inhibitor
797 174/358 (48.6%) 259/439 (59%) MAP 70–90 mmHg CI ≥ 3 l/min/m2
CI, cardiac index; CVP, central venous pressure; DO2I, Oxygen Delivery Index; EGDT early goal-directed therapy SVO2, venous oxygen saturation; MAP, mean arterial 
pressure; PAOP, pulmonary artery occlusion pressure; SBP, systolic blood pressure.Critical Care    Vol 11 No 3    Sevransky et al.
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included specific hemodynamic goals. It is noteworthy that the
four largest clinical studies evaluating novel therapies in
patients with sepsis – evaluating drotrecogin alpha, tissue fac-
tor pathway inhibitor, antithrombin III, and monoclonal antibod-
ies to TNF [27-30] – did not specify hemodynamic goals.
Only three studies included specific fluid challenge as part of
their protocol [10,12,14]. All three included specific volume
challenge boluses to reach a desired filling pressure, but all
included different fluid-dosing and filling pressure goals. Ade-
quate volume resuscitation remains a key component in the
treatment of septic patients. While the filling pressure may
represent a measure of the adequacy of resuscitation, a recent
report suggests that filling pressure goals alone do not corre-
late well with changes in the stroke volume index [31].
The present systematic review has several potential limita-
tions. First, the heterogeneity of populations and therapies
prevents synthesis of findings regarding the hemodynamic
goals on treatment outcomes It may not be possible to gener-
alize information about treatment paradigms across these
differing studies with agents with variable mechanisms of
actions. The variation in treatment goals seen across these
studies, however, provides evidence that practice patterns
remain heterogeneous in the provision of hemodynamic sup-
port. Standardized treatment protocols have been imple-
mented in recent years in critically ill populations, including
include standard ventilatory weaning methods [32], protocol-
ized ventilatory strategies for patients with acute lung injury
[33,34], and insulin therapy goals [35,36]. Broad use of pro-
tocols to achieve hemodynamic goals in patients with sepsis,
however, remains elusive.
Second, we did not include studies of patients who were at
risk for developing sepsis. We therefore cannot extrapolate
our findings to the general critically ill population. It is possible
that those studies of the 'at-risk population' would lead to
important information about the use of hemodynamic goals in
critically ill populations. However, our study does provide infor-
mation on those patients with established sepsis. We chose
Figure 2
Hemodynamic goals in sepsis trials Hemodynamic goals in sepsis trials. (a) Mean arterial pressure (MAP) goals in sepsis trials. (b) Central venous pressure (CVP) goals in sepsis trials. 
(c) Pulmonary artery occlusion pressure (PAOP) goals in sepsis trials. (d) Cardiac index in sepsis trials. For studies that provided an interval goal 
range, the mean of the range is graphed. One study provided a separate CI for the treatment and control groups; these are graphed separately.Available online http://ccforum.com/content/11/3/R67
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to focus on patients with sepsis since adequate supportive
care with fluid and vasopressors remains one of the main ten-
ets of therapy for patients with sepsis.
The wide range of hemodynamic goals in the selected studies
underscores the lack of convincing data to support one hemo-
dynamic goal over another, but raises the possibility that these
goals may modify treatment effects of specific agents. Hemo-
dynamic therapy is a vital portion of the treatment strategy, and
it remains biologically plausible that agents affecting blood
pressure and cardiac output may modify the effects of specific
anti-sepsis agents. The choice of vasopressor agents for
patients with septic shock may also modify the effects of such
anti-sepsis agents.
The lack of specific hemodynamic measures and goals
observed in the present systematic review may reflect the var-
iation in clinicians' general beliefs and practice, or may reflect
differences in patient populations studied. The heterogeneous
patient population that develops sepsis (for example, elderly
patient with urosepsis, young trauma patient with intraabdom-
inal sepsis, brain-injured patient with ventilated-acquired pneu-
monia), however, may preclude the use of a single
hemodynamic goal for all septic patients. The recently pub-
lished surviving sepsis campaign guidelines do provide basic
guidelines for resuscitation goals, but they suggest that the
treatment goals may be individualized based on patient
response to therapy [4].
Conclusion
Fewer than 30% of all clinical trials in the field of sepsis have
mandated hemodynamic treatment goals for patient manage-
ment. For those studies that do report hemodynamic goals of
therapy, there are wide variations in the measures followed
and the goals chosen. If hemodynamic goals are related to out-
comes and to specific agents, the variation in hemodynamic
goals may introduce bias into clinical trials in sepsis patients.
Further research is needed to determine whether standardiza-
tion of measures and target goals for hemodynamic monitoring
may improve clinical research in the field of sepsis.
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Table 3
Quality assessment of trials
Reference Sepsis criteria explicitly stateda Volume challenge explicitly stated Jadad and colleagues [9] score 
analysis
Tuchsmidt and colleagues [12] Yes Yesb 1
Peake and colleagues [10] Yes Yesc 2
Bollaert and colleagues [11] Yes No 2
Spapen and colleagues [19] Yes No 2
Alia and colleagues [18] Yes No 1
Boldt and colleagues [15] Yes No 1
Clark and colleagues [23] Yes No 3
Briegel and colleagues [17] Yes No 2
Rivers and colleagues [14] Yes Yesd 3
Cole and colleagues [13] Yes No 1
Emet and colleagues [16] Yes No 2
Bakker and colleagues [20] Yes No 3
Lopez and colleagues [21] Yes No 2
aAmerican College of Chest Physicians/Society of Critical Care Medicine criteria [8]. b5% albumin in aliquots to achieve pulmonary artery 
occlusion pressure > 15 mmHg. c200 ml bolus over 15 minutes to achieve a sustained increase in pulmonary artery occlusion pressure ≥ 3 
mmHg. d20–30 ml/kg initial fluid bolus over 1 hour followed by 500 ml every 30 minutes to achieve central venous pressure of 8–12 mmHg.
Key messages
￿  Most sepsis clinical trials reviewed did not include 
hemodynamic goals of therapy. Of note, the four largest 
clinical trials evaluating novel therapies in patients with 
sepsis did not specify hemodynamic goals of treatment.
￿  For those 13 studies identified in our systematic review, 
there was wide variation in hemodynamic measures 
selected and the hemodynamic goals chosen.
￿  Further research is necessary to determine whether this 
lack of consistency in hemodynamic goals may contrib-
ute to heterogeneity in treatment effects for clinical trials 
of novel sepsis therapies.Critical Care    Vol 11 No 3    Sevransky et al.
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